Cullinan Therapeutics, Inc.

Cullinan Therapeutics, Inc.

CGEM·NASDAQ

$15.21

-0.85%
HealthcareMedical - Pharmaceuticals

Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.

At a Glance

Live Snapshot
Market Cap$934.78M
EPS-3.7200
P/E Ratio-4.09
Earnings Date08/06/2026

cgem

Net Change in Cash

Last Annual Value

5.33M

3-Year CAGR

-62%

5-Year CAGR

-45%

10-Year CAGR

9%

Cullinan Therapeutics, Inc.

Cullinan Therapeutics, Inc. Competitors Analysis of Net Change in Cash

CGEM · NASDAQ
CompanyNet Change in Cash
CAGR 3Y
CAGR 5Y
CAGR 10Y
5.33M
N/AN/AN/A 
-23.30M
N/AN/AN/A
CBLL logo
CeriBell, Inc.
NASDAQ:CBLL
-153.89M
N/AN/AN/A
EHAB logo
Enhabit, Inc.
NYSE:EHAB
15.20M
80.1%N/AN/A
-48.17M
N/AN/AN/A
39.17M
-33.5%-29.0%N/A
122.26M
142.9%N/AN/A
6.26M
N/A-41.4%22.0%
Cullinan Therapeutics, Inc.

Cullinan Therapeutics, Inc. Fair Value Envelope

CGEM · NASDAQ

Our analysis suggests that CGEM has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $15.21, this represents a potential HIDDEN relative to our calculated worth for Cullinan Therapeutics, Inc..

Intrinsic Value
Current Price: $15.21